Compass Therapeutics (CMPX) Earnings Date & Reports

Key Takeaways

• Wall Street expects a net loss of roughly $0.12 to $0.13 per share for the third quarter of 2026, compared with a loss of $0.08 per share in the same period a year earlier.
• Consensus revenue is minimal—around $0.23 million—consistent with Compass Therapeutics' status as a pre-revenue, clinical-stage biotech.
• The company reported a loss of $0.13 per share in the second quarter of 2026, missing the $0.11 consensus estimate, and has beaten EPS (earnings per share) estimates in three of its last eight quarters.
• With no product sales, investors are watching cash position, R&D (research and development) spending, and clinical milestones for tovecimig and CTX-8371.
• Analysts maintain a consensus "Moderate Buy" rating, though price targets span a wide range.
• For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover actionable market ideas with Trending AI Robots.

Earnings Context and Why It Matters

Compass Therapeutics, Inc. (CMPX) is a Boston-based, oncology-focused biopharmaceutical company developing antibody-based therapies, and it currently generates essentially no product revenue. That makes its quarterly earnings release less about top-line sales and more about two things: how quickly it is burning cash and how its clinical pipeline is advancing. The company's lead candidate, tovecimig (a DLL4 x VEGF-A bispecific antibody), reported positive Phase 2/3 data earlier in 2026 in biliary tract cancer, while CTX-8371 (a PD-1 x PD-L1 bispecific antibody) is advancing through early-stage studies. For investors, the Q3 2026 report is a checkpoint on spending discipline, cash runway, and management's updated clinical timeline.

Earnings Expectations

Compass Therapeutics is expected to report results for the third quarter of 2026, the three-month period ended September 30, 2026. The company follows a standard calendar fiscal year. Consensus estimates point to a net loss of approximately $0.12 to $0.13 per share, with revenue of roughly $0.23 million. In the year-ago quarter, the company posted a narrower loss of $0.08 per share, so analysts are modeling a wider loss on a year-over-year basis.

Recent history shows a mixed track record. In the second quarter of 2026, Compass reported a loss of $0.13 per share, missing the $0.11 consensus estimate by $0.02. For the full year 2026, analysts currently project a loss of about $0.47 to $0.48 per share, with a similar loss of roughly $0.49 to $0.52 expected in 2027. Because the company is pre-revenue, the headline EPS figure matters less than the balance-sheet metrics investors will scrutinize: cash and investments on hand, quarterly R&D (research and development) and general spending, and any updated runway commentary.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, helping investors quickly narrow a broad universe to the names that match their specific criteria. Explore the AI Screener to build a focused watchlist around earnings events like this one.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter 2026 report has been shaped less by the earnings print itself and more by clinical catalysts and financing concerns. Shares pulled back sharply from their 52-week high earlier in 2026, and the stock has traded well below those levels in recent weeks. For a pre-revenue biotech, the market's reaction to an earnings release is often muted compared with the swings triggered by data readouts. Key risk factors include the pace of cash consumption, the potential for additional equity offerings, and any changes to the timing of the tovecimig and CTX-8371 programs. Investors will also weigh whether the company reaffirms its stated cash runway, which management and analysts have previously described as extending into 2027 or 2028.

Forward Outlook and Key Factors to Monitor

Looking beyond the third-quarter report, the most important variables for Compass Therapeutics are clinical and operational rather than purely financial. Investors should watch for updated guidance on the cash runway and any commentary on spending trajectory, since the company remains unprofitable and dependent on its cash reserves to fund development.

The tovecimig program in biliary tract cancer is the central near-term catalyst. After reporting statistically significant progression-free survival (PFS, a measure of how long patients live without their disease worsening) improvements earlier in 2026, the company has been expected to advance toward a potential Biologics License Application (BLA), the formal request for regulatory approval. The timing and scope of that submission will be closely watched.

Separately, the CTX-8371 bispecific antibody is enrolling expansion cohorts in several tumor types, and additional early-stage data could shape sentiment. Investors should also monitor R&D expense trends, any changes to collaboration or financing plans, and the broader oncology-funding environment. As always, these factors carry meaningful uncertainty, and clinical or regulatory setbacks could materially affect the outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations